Condition deep-dive · 6 min read

Chronic Rhinosinusitis — supplement protocol

Updated 2026-05-19 · Reviewed by SupplementScore editors · No sponsorships

Chronic rhinosinusitis (CRS) is inflammation of the paranasal sinuses lasting 12+ weeks, with subtypes including CRS with nasal polyps (CRSwNP) and without (CRSsNP). Standard care is daily saline irrigation, intranasal steroids, and (where indicated) biologics or surgery — ENT-directed. Supplements have a narrow but real adjunct role, mainly targeting the inflammatory and mucociliary substrate. The biggest "supplement" interventions here are arguably saline rinses themselves and vitamin D correction; the rest is icing.

Get the phenotype right first. CRS with polyps, without polyps, and with comorbid AERD (aspirin-exacerbated respiratory disease) have different drivers and different first-line treatments. Recurrent acute sinusitis is a different problem. Persistent unilateral symptoms, bloody discharge, or facial numbness warrant ENT urgent assessment to exclude tumour or fungal disease. The protocol below assumes a CRS diagnosis from an ENT or experienced primary-care provider.

The mainstay — high-volume saline irrigation

Twice-daily large-volume isotonic or hypertonic saline irrigation (Neil-Med, NeilMed Sinus Rinse, or generic equivalent) is the most-evidenced single intervention in CRS — recommended by EPOS 2020 and AAO-HNS guidelines as a baseline for nearly every patient. It is, technically, a supplement-like intervention even though most regard it as part of standard care. Add intranasal budesonide or fluticasone "off-label" via the rinse bottle under ENT direction for CRSwNP — this has good trial support.

The supplement stack — evidence-based adjuncts

Layer 1 · Correct deficiency

Vitamin D3 — test, then supplement to target

1000–2000 IU/day; target serum 25-OH-D 30–50 ng/mL

Vitamin D insufficiency is associated with worse CRS — particularly CRSwNP. Schlosser 2017 and subsequent observational data show inverse association between 25-OH-D and polyp burden. Trial-level interventional evidence is thinner. Test status; supplement to correct if deficient. Inexpensive and broadly beneficial.

Layer 2 · Inflammation modulation

Omega-3 (EPA/DHA)

1–2 g EPA+DHA/day with food

Modest anti-inflammatory effect; small signals on eosinophilic CRS markers in some studies. The cardiovascular adjacency adds value. For CRSwNP particularly, the rationale is stronger.

Layer 2 · Mast-cell / allergic component

Quercetin (phytosome form)

250–500 mg b.i.d. of quercetin phytosome (improved bioavailability)

For patients whose CRS has a clear allergic or mast-cell-driven component, quercetin's mast-cell-stabilising activity offers a low-risk adjunct. Effect is modest; useful in stacking with antihistamines and intranasal steroids.

Layer 3 · Mucolytic / mucociliary support

N-Acetyl Cysteine (NAC)

600 mg b.i.d.

NAC has mucolytic activity (breaks disulfide bonds in mucus glycoproteins) and antioxidant effects. Italian observational data and small RCTs suggest benefit in CRS symptoms and mucociliary function. Useful when mucus thickness is a dominant complaint.

Layer 4 · Inflammation adjunct for acute exacerbations

Bromelain (enzyme)

500 mg 3x/day on empty stomach for 5–7 days during acute flares

Bromelain has German trial data as an adjunct to standard care in acute sinusitis (Braun 2005) for symptom duration and severity. Useful during exacerbations rather than as chronic prophylaxis. Take away from meals to maximise systemic effect; check interactions with anticoagulants.

Optional · For polyp burden specifically

Manuka honey nasal rinse (with caution)

Per ENT direction — not a self-care recommendation

Several pilot studies of manuka honey rinses for biofilm-driven CRS show modest signal. This is an ENT-directed intervention because of preparation sterility and concentration concerns; do not improvise at home.

What to skip

Echinacea, garlic, "immune boosters" — no trial-level evidence for CRS prevention or treatment; some interaction concerns.
Decongestant nasal sprays (oxymetazoline) beyond 3 days — rebound rhinitis (rhinitis medicamentosa) makes CRS worse.
Antibiotics without microbiological indication — long-course macrolides have a niche role in some CRSsNP phenotypes; not for self-administration.
"Lung cleanse" / "sinus detox" products — not real categories of intervention.
High-dose zinc nasal sprays — irreversible anosmia has been reported with zinc gluconate intranasal products. Avoid intranasal zinc preparations.

Environmental and lifestyle layer

Allergen exposure reduction — dust-mite covers, HEPA filtration, pet-dander minimisation if allergic.
Smoke and irritant avoidance — tobacco smoke and wood-smoke exposure substantially worsen CRS.
Humidification — particularly in dry climates and winter; cool-mist humidifier with regular cleaning.
Allergy workup — skin or serum IgE testing for relevant aeroallergens if not already done.
Reflux consideration — laryngopharyngeal reflux can mimic or worsen postnasal-drip-type CRS symptoms.

The escalation ladder

Saline irrigation + intranasal steroid + supplement adjuncts for 12 weeks. If symptoms persist: ENT referral for nasal endoscopy, CT imaging, and consideration of off-label budesonide rinses (CRSwNP), short oral corticosteroid courses, or surgery (functional endoscopic sinus surgery — FESS). For severe CRSwNP, modern biologics (dupilumab, omalizumab, mepolizumab) have transformed care over the past 5 years — discuss with ENT or allergy.

Practical quick-start. Daily large-volume saline irrigation, intranasal corticosteroid as prescribed, vitamin D test/correct, omega-3 1.5 g/day, NAC 600 mg b.i.d. if mucus thickness is a complaint, quercetin phytosome 500 mg b.i.d. if allergic. Reassess at 12 weeks; if no improvement, escalate to ENT for endoscopic/CT evaluation and biologics or surgery as appropriate.

Educational reference, not medical advice. Discuss any supplement change with a qualified clinician before acting on this list. CRS can mimic more serious sinonasal pathology; persistent unilateral symptoms warrant prompt ENT assessment.